XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration
September 19, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical...
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2022
September 01, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study
August 22, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration
August 04, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Reports Annual & Special Meeting Results
July 22, 2022 08:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, July 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces Submission to European Medicines Agency
July 19, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, July 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial
July 13, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, July 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)
July 07, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces “Fireside Chat” with XORTX CEO
June 21, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX to Present at BIO International Convention 2022
June 13, 2022 08:55 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...